Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex (NYSE: TFX) reported Q1 2026 continuing operations revenue of $548.3M, up 32.3% year-over-year and 5.1% on a pro forma adjusted constant currency basis. GAAP diluted EPS was $(0.11); adjusted diluted EPS was $1.39. Company reaffirmed full-year 2026 guidance: GAAP revenue growth 14.4%–15.4%, adjusted EPS $6.25–$6.55, and expects Strategic Divestitures to close in H2 2026.
Key balance-sheet notes: cash $329.6M, inventories $380.9M, net AR $365.5M; stranded costs estimated at $90M; intends ~$1B buyback and ~$800M debt paydown.
Teleflex (NYSE: TFX) appointed Jason Weidman as President and CEO, effective June 8, 2026. He will join the board upon assuming the role and succeeds Stuart Randle, who remains a director. The company said Weidman brings 25+ years in medical technology and global operating-unit experience.
Teleflex noted pending divestitures and an intended capital plan including a $1.0 billion share buyback and $800 million debt paydown to reposition the company toward interventional, critical care, and high-acuity hospital markets.
Teleflex (NYSE:TFX) will host a conference call to discuss its first quarter 2026 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 7, 2026.
Investors can pre-register to receive dial-in details, listen via a live audio webcast at teleflex.com, and access an audio replay beginning at 11:00 a.m. Eastern Time on May 7, 2026 (conference ID 69028).
Teleflex (NYSE:TFX) announced Board and governance changes on April 9, 2026, including the nomination of Michael J. Tokich as an independent director and the appointment of Andrew A. Krakauer as Chairman effective after the 2026 Annual Meeting.
The Board will form a Growth and Operating Committee to support transformation efforts, and the company plans to commence opportunistic share repurchases under its existing $1 billion authorization beginning in Q2 2026, subject to market conditions and cash flow needs.
Irenic Capital Management, a 2% shareholder in Teleflex (NYSE: TFX), urged the Teleflex board to form a Strategic Review sub-committee with new independent directors, a shareholder representative and exclusion of Dr. Klasko to oversee inbound and outbound strategic processes and report back to shareholders.
Irenic said it disagrees with the board's description of their prior conversation and said it looks forward to working with the board to maximize shareholder value.
Teleflex (NYSE:TFX) reiterated its value-maximizing plan following engagement with activist Irenic on March 19, 2026. The company expects previously announced sale transactions to close in the second half of 2026, yielding approximately $1.8 billion of net proceeds after tax.
Teleflex plans to allocate proceeds to a $1.0 billion share repurchase and $800 million debt paydown, pursue a multi-year restructuring targeting about $50 million annual pre-tax savings by mid-2028, and complete announced divestitures while continuing its CEO search.
Summary not available.
o9 announced that Teleflex (NYSE: TFX) went live globally on o9's platform for integrated Demand Planning and Supply Planning on March 12, 2026.
This deployment connects demand forecasts and supply plans in one environment, improving cross-functional coordination, inventory and capacity visibility, forecast performance, and alignment on trade-offs across regions and functions.
Teleflex (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share. The dividend is payable March 31, 2026 to shareholders of record at the close of business on March 6, 2026.
Shareholders registered by the record date will receive the March 31 payment; more corporate details are available from the company.
Teleflex (NYSE: TFX) reported full-year 2025 continuing operations GAAP revenue of $1,992.7M (+17.2%) and adjusted revenue of $1,983.7M (+16.3%). Adjusted diluted EPS from continuing operations was $6.98.
Management provided 2026 outlook: GAAP revenue growth 14.4%–15.4%, pro forma adjusted constant currency revenue growth 4.5%–5.5%, and adjusted diluted EPS $6.25–$6.55. Company announced strategic divestitures, expected H2 2026 close, estimated $1.8B after-tax proceeds, and an initial restructuring to mitigate $48M–$52M annual stranded costs.